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A common challenge encountered during development of high concentration monoclonal 
antibody formulations is preventing self-association. Depending on the antibody and its 
formulation, self-association can be seen as aggregation, precipitation, opalescence or phase 
separation.  Here we report on an unusual manifestation of self-association, formation of a 
semi-solid gel or “gelation”.  Therapeutic monoclonal antibody C4 was isolated from human B 
cells based on its strong potency in neutralizing bacterial toxin in animal models.  The purified 
antibody possessed the unusual property of forming a firm, opaque white gel when it was 
formulated at concentrations >40 mg/mL and the temperature was <6oC.  Gel formation was 
reversible and was affected by salt concentration or pH, suggesting a charge interaction 
between IgG monomers. However, formulation optimization could not completely prevent 
gelation at high concentrations so a protein engineering approach was sought to resolve the 
problem.   
A comparison of the heavy and light chain amino acid sequences to consensus germline 
sequences revealed 16 amino acid sequence differences in the framework regions that could be 
involved with gelation.  Restoring the C4 framework sequence to consensus germline residues 
by targeted mutagenesis resulted in no gel formation at 50 mg/ml at temperatures as low as 
0oC.  Additional genetic analysis was used to identify the key residue(s) involved in the gelation. 
A single substitution in the native antibody, replacing heavy chain glutamate 23 with lysine, was 
found sufficient to prevent gelation, while a double mutation, replacing heavy chain serine 85 
and threonine 87 with arginine, increased the temperature at which gel formation initiated.  
These results indicate that the temperature dependence of gelation may be related to 
conformational changes near the charged residues or the regions interact with.  Our work 
provided a molecular strategy that can be applied to improve the solubility of other therapeutic 
antibodies.  
 
